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Abstract 
The reactions of dopamine (1-amino-2-(3,4-dihydroxyphenyl)-ethane, DA), 5-hydroxydopamine (5-OHDA), and 6-hydroxydopamine 
(6-OHDA), with molecular oxygen - -  with and without he addition of catalytic amounts of iron(Ill) and other metal ions - -  have been 
studied and the implication of these results with respect to the chemistry involved in the progress of Parkinson's disease is discussed. In 
the presence of 02 DA reacts pontaneously without he necessity of metal-ion catalysis under the production of stoichiometric amounts 
of H202, to form initially pink dopaminochrome, which is not stable and reacts further (without he consumption of dioxygen) to form 
the insoluble polymeric material known as 'melanine'. DA reacts with iron(Ill) yielding an intermediate 1:1 complex, which decomposes 
releasing Fe(II) and the semiquinone, which reacts further under involvement of both Fe(III) and dioxygen. 6-OHDA reacts without 
showing the necessity of such an intermediate, and it is shown to be able to release iron as Fe(II) from ferritine. On the other hand, it is 
shown (in vitro) that Fe(II) reacts in a Fenton type reaction with DA and the present H202 producing 5-OHDA and especially 6-OHDA. 
Based on these mutual interacting reactions a mechanism for the initiation and progress of Parkinson's disease is suggested. The catalytic 
effects of some other transition-metal ions are presented and an explanation for the peculiarly toxic effects of manganese(II) is put 
forward. Finally, a possible reason for the effect that nicotine has in the mitigation of Parkinson's disease is discussed. 
Keywords: Parkinson's disease; Dopamine; 6-Hydroxydopamine; Iron(liD; Iron(II); Manganese(II); Fenton's reagent; Nicotine 
1. Introduction 
1.1. Chemical aspects 
Dopamine is 1-amino-2-(3,4-dihydroxyphenyl)ethane, 
existing in neutral solution as the protonated form, I, and, 
where necessary in this paper, is 
HO,,t  g NH 3 
Dopamine, I 
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referred to as H2LH +, where the phenolic protons are 
written to the left of L. The protonation equilibria for the 
anion have been determined by Gergely and Kiss [1] and 
are listed in Eq. (1), Eq. 0, below. (Note that here the 
dopamine anion is written as H3 L+, since these are macro- 
constants and therefore cannot be assigned to specific 
protonations.) 
L2 -+ H+~ HL - logK~ = 13.1 
HL-+ H+~ H2L IogK2 H = 10.41 (1) 
H2L + H+~ H3 L+ logK3 H = 8.82 
When a neutral solution of dopamine, I, is exposed to air 
it, after a while, turns pink due to its oxidation (via several 
steps) to dopaminochrome, II, even when transition-metal 
ions are strictly excluded. The pink colour then slowly 
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disappears to be replaced by a precipitate of the polymeric 
material known as melanin. 
Dopaminochrome,  II 
The addition of acid inhibits the reaction unless metal 
ions such as Fe 3+, Cu 2+, or VO 2+ are present. 
However, the markedly different behaviour of the 
closely related - -  both chemically and biochemically - -  
catecholamines adrenaline (1-(3,4-dihydroxyphenyl)-2- 
(methylamino)-ethanol), Il , and dopa (3-(3,4-dihydroxy- 
phenyl)alanine), IV, should be noted. In the rigorous ab- 
sence of metal ions they are stable towards oxidation 
N~CH 3 
Adrenaline, III 
Dopa, I V 
by dioxygen even in neutral solution [2,3]. 
In acid solution (pH < 4.5) the metal-ion catalysed oxi- 
dation of dopa proceeds moothly to completion [4]. In the 
case of dopamine, however, although added metal ions 
initially start an oxidation process, this soon comes to an 
end because the metal ions are efficiently removed from 
the solution by the final product, melanin, or by a soluble 
precursor of it. The involvement of metal ions in this 
reaction is now being studied in greater detail. 
1.2. Medical aspects 
Some populations of melanised neurons of the brain 
have been shown to be selectively vulnerable [5] in that, in 
contrast to most other neurons of the lower brain stem [6], 
they show an increased rate of degeneration in both normal 
ageing and in the development of Parkinson's disease 
(PD). These dopaminergic neurons are also specifically 
sensitive to manganese, 1-methyl-4-phenyl-l,2,3,6-tetrahy- 
dropyridine (MPTP), 6-hydroxydopamine (6-OHDA) and 
to the, as yet unidentified, factors [7] that are presumed to 
give rise to PD. In this respect the apparent interplay 
between 'pro-neurotoxins' such as MPTP and 6-OHDA 
that can be converted by monoamineoxidase-B (MAO-B) 
into neurotoxins i  not yet fully understood. It has been 
suggested [8] that an alternative mechanism for the alleged 
antidegenerative action of the MAO-B inhibitor, deprenyl, 
could be inhibition of the formation of H202 and oxygen 
radicals by MAO. The destruction of pigmented brain stem 
nuclei, particularly those of the Substantia nigra (SN) 
appears to be the key to the pathogenesis and pharmacol- 
ogy of PD [9]. Although the cause of dopaminergic cell 
death remains unknown, excess iron within the SN has 
been implicated in the progression of the disease through 
its participation in the continuous formation of cytotoxic 
free radicals [10]. 
Based on the demonstration of this increase in 'free' 
iron in the SN of the brains of deceased patients who had 
suffered from PD [11], together with its accumulation on 
melanin particles in the remaining cells [12] it has recently 
been proposed [13] that iron-melanin interactions may be 
involved in the degeneration of dopaminergic neurons. A 
possible mechanism that leads to an increase in the level of 
iron not protected by being bound to ferritin is thus 
required. This decompartmentation of iron (or 'tissue iron 
overload') is known [14] to lead to a state of oxidative 
stress, and it is highly relevant hat many cytotoxic om- 
pounds that readily promulgate redox reactions can release 
iron from storage, a well-documented xample is that of 
paraquat toxicity of the lung which has been linked [15] to 
the ability of paraquat to completely release the iron from 
ferritin. Again, studies have demonstrated that, in rats, 
intraventricular p e-injection of desferral (a selective iron 
chelator) attenuates 6-OHDA induced lesions of nigrostri- 
atal dopamine neurons [14]. This was made evident by the 
prevention of loss of striatal DA and the reduction of 
homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic 
acid (DOPAC) (usually observed after injection with 6- 
OHDA). 
1.3. Relevance of the in c~itro studies 
Seen in the light of the above observations, the follow- 
ing in vitro studies would seem to shed some light on the 
rale of iron and of 6-OHDA in the progression of PD. 
Firstly, it is shown that uncomplexed iron(II) is able to 
react with H202 thus promoting a Fenton-like reaction 
that, via formation of the cytotoxic hydroxyl radical, con- 
verts dopamine to 5-OHDA and 6-OHDA. 
Secondly, it was demonstrated by stopped-flow spec- 
troscopy that whereas dopamine and 5-OHDA were oxi- 
dised by iron(liD via complex formation, the correspond- 
ing oxidation of 6-OHDA proceeded via an 'outer-sphere' 
interaction. This predicted, correctly, that 6-OHDA alone 
is capable of releasing iron from strongly co-ordinating 
ligands, i.e., from ferritin. 
Thirdly, kinetic studies of the reaction between 
dopamine and dioxygen, with and without iron(Ill) being 
present, showed that neither melanin nor iron-containing 
melanin played a part in this reaction and that although 
162 w. Linert et al. / Biochimica et Biophysica Acta 1316 (1996) 160-168 
iron(III) can initiate this reaction (even in acid media) it is 
not a catalyst. (The iron(III) is efficiently removed from 
the solution as an inert soluble complex and is eventually 
trapped within the melanin formed.) [16-18]. 
Finally, similar studies with manganese(II) showed that 
it does act as an efficient catalyst for the oxidation of 
dopamine, because it is not trapped in the melanin (or by 
a soluble precursor of the melanin). 
Dopamine has, therefore, attracted much attention due 
to its postulated role in both Parkinson's and Alzheimer's 
diseases [19,20]. Especially important in this respect is the 
above mentioned role of the products of its oxidation and 
the rale of the iron-containing melanins found in the SN of 
deceased Parkinsonian patients [7,13,21-23]. This, to- 
gether with our (E.H., R.F.J., and W.L.) interest in the role 
of co-ordination complexes in transition-metal ion catal- 
ysed autoxidation reactions, has stimulated the present 
study. 
2. Materials and methods 
2.1. Chemicals 
by use of both, a Tracor Northern TN-1710 diode-array 
and SX17.MV microvolume high-speed stopped flow spec- 
trometer (both supplied by Applied Photophysics, Leather- 
head, UK). 
All kinetic studies were carried out at a constant ionic 
strength of 0.100 M by use of potassium chloride as 
background electrolyte. The iron concentration was chosen 
such that an effect could be made visible in an appropriate 
time. Extrapolations to physiological iron concentrations 
are nonetheless possible. 
Iron release from ferritin was measured using the fer- 
rous chelator ferrozine as a chromophore. The amount of 
Fe(II) released was evaluated spectophotometrically based 
on a molar absorption of e562 = 27.9 mM-I  cm-~ of the 
complex for a reaction mixture (1 ml final volume) con- 
taining 50 mM Hepes buffer (pH 7.0), 500 IxM ferrozine 
and the other reagents (6-OHDA). The reactions were 
performed at 37°C against reference cuvettes containing all 
reactants except ferritin and initialised by the addition of 
6-OHDA. The increase in absorption at 562 nm was 
continuously monitored using a standard spectrometer. 
Values accepted were the means of three replicate incuba- 
tions. 
The dopamines were obtained as the hydrochlorides 
from the Sigma Chemical Co. and used without further 
purification. (Replacement of the chloride ions by nitrate 
- -  by use of ion-exchange resins - -  for some runs was 
used to confirm that chloride did not, in general, influence 
the reactions being studied.) Whenever possible analytical 
grade reagents were used. Synthetic melanins were pre- 
pared by autoxidation according to Das et al. [24]. 
Iron(III) nitrate, manganese(II) sulfate, copper(II) ni- 
trate, oxovanadium(IV) sulfate, sodium dihydrogen phos- 
phate, and dipotassium hydrogen phosphate were supplied 
as the hydrated salts by Merck; all were of pro analysi 
quality. EPPS buffer (3- (4- (2-hydroxyethy l ) - l -  
piperazino)-propanesulfonic ac d) was from Aldrich. Cata- 
lase (from bovine liver) was obtained from Sigma. 
2.2. Kinetic studies 
2.3. Chromatography 
The reversed phase HPLC determinations were carried 
out using a Model 5000 solvent delivery module, a 
Coulochem 5100 A detector, and a 5010 analytical cell (all 
by ESA) connected to a CI-10 recording integrator 
(LDC/Milton); potential differences were +0.46 V and 
-0 .22 V, respectively. Samples were introduced using a 
100 p.l injection loop and separations carried out using a 
250 × 4.6 mm ID LC-18 column (5 t~m average particle 
size). The mobile phase (pH 3) contained 20 mM potas- 
sium dihydrogen phosphate, 0.4 mM octane sulfonic acid, 
and 14% methanol (v/v).  The flow rate of the mobile 
phase was 1.0 ml/min. (Prior to use, the mobile phase was 
filtered through a 0.22 mm membrane filter (Sartorius).) 
Peak identifications were established by admixture with 
authentic standards. 
Oxygen consumption was measured with a Clark-type 
electrode (EO96: WTW) connected to the corresponding 
processor unit (Oxi537: WTW) and the output recorded on 
a Goertz-Metrawatt x- t  recorder. The pH was kept con- 
stant to within _+0.01 pH units with an RTS822 titrating 
unit coupled to a PHM84 pH meter (both by Radiometer) 
enabling the rate of addition of base (or acid) to be 
monitored. The temperature was maintained to within 
+ 0.05°C by a K2 Ultrathermostat (Lauda). The reaction 
vessel, and its mode of operation, has been described 
previously [16]. Samples were occasionally withdrawn in 
order to record UV-Vis spectra on a Hitachi U-2000 
spectrometer. 
Anaerobic kinetic data and spectra were also obtained 
3. Results and discussion 
3.1. The autoxidation of  dopamine in the absence of  metal 
ions 
The course of the uncatalysed autoxidation of DA is 
shown in Scheme 1. 
The kinetics of this reaction have been studied in some 
detail [16] and these can be summarised as follows: The 
consumption of oxygen is accurately first-order in oxygen 
for over three half-lives and is independent of ambient 
light. Protons are released uring the reaction at an identi- 
cal rate the oxygen consumption. The rate constants are 
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Scheme 1. 
inversely proportional to [H +] and directly proportional to 
the total concentration of dopamine, [L]T. The rate law is 
therefore: 
- d[O 2 ]~dr = A[L]T/ [H + ][02 ] (2) 
The amount of added base (calculated from the inter- 
cept of the first-order plot) is independent of pH and 
dopamine concentration and for initially saturated oxygen 
solutions was found to be 0.061 + 0.008 mmol. This is 
approximately half the initial amount of oxygen (0.132 
mmol [25]), i.e., one proton is released for every two 
oxygen molecules consumed. The production of peroxide 
was demonstrated by stoichiometric recovery of oxygen 
after addition of catalase to a reacted solution. The stoi- 
chiometry of the reaction is therefore: 
H2LH++ 202 ~ HQ* + H++ 2H202 (3) 
The obtained rate law has been interpreted that the 
reaction being followed is the rate-determining abstraction 
of a hydrogen atom from the monodeprotonated dopamine, 
HLH, and that all subsequent steps shown in Eq. (4) are 
fast [26-28]. Since dopaminochrome is considered a final 
product of the oxygen-consuming and the proton-releasing 
reactions, its further reaction to melanin must involve 
neither protons nor oxygen. However, a contribution of a 
catalytic amount of hydroxyl radicals from the cleavage of 
an extremely small amount of the hydrogen peroxide 
produced is a possible candidate for initiating this poly- 
merisation reaction. Allowing for the consumption of a 
second oxygen molecule by leucadopaminochrome, A can 
be interpreted as 2 k I Km °H ; K °H being the microconstant 
for the deprotonation of the phenol site (pK °H = 8.90 [1]). 
This yields a value k~ of 0.47 _+ 0.05 M- J s-  ~ at 25°C at 
an ionic strength of 0.100 M (C1-). The variation with 
temperature establishes an apparent activation energy of 75 
kJ tool- ~. 
H2LH +¢* HLH + H + 
HLH + O z-~ LH '+ H++ O~ 
LH '+ O, ~ QH++ O~ (4) 
HO~ + 0 2 + H+~ H202 + O~ 
QH + --+ H2L ~ + H + 
H2L* + O, --+ HQ* + H202 
3.2. Effect of metal ions on the reaction of dopamine with 
dioxygen 
The effects of added metal ions on the autoxidation of 
dopamine are summarised in Table 1. It can be seen that 
Fe(III), and VO 2+ have little, if any, influence on the rate 
of autoxidation, and this might well be because the metal 
ion becomes encapsulated by an inert, probably polymeric, 
but soluble, precursor of melanin. Neither melanin itself 
nor metal-ion-containing melanin has any effect on the rate 
at neutral pH. The unreactivity of Cu(II), on the other 
hand, might be due to the effect of chlorocomplexes on the 
Cu(II)/Cu(I) redox couple (chloride-free solutions have 
not been examined in this case). 
In acid solution, iron(III) (and several other metal ions) 
initiates the reaction of dopamine with dioxygen, but is not 
a true catalyst because reaction ceases when 1 tool of 
Table 1 
The effect of metal 
raM, pH = 7.60) 
ions (100 p.M) on the autoxidation of DA ([L] T = 10 
Metal kob ~ (10 4 S-I)  kob~M / kobsnonM 
none 7.2 1.0 
Fe(II) 5.6 0.8 
Fe(IIl) 6.7 0.9 
Zn(II) 6.6 0.9 
Cu(II) 8.6 1.2 
VO 2+ 10.6 1.5 
Ni(II) 17.2 2.4 
Mn(II) 29.l  (3.7 * ) 4.0 
Co(l l)  46.2 * * 6.4 
* Half-order ate constant (units of  10 -5 M I/2 s i). 
* Possible half-order contribution. 
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oxygen is consumed per mol of iron. The reason for and 
the nature of the reaction is being investigated at present 
(E.H., R.F.J., and W.L.) but it demonstrates that Halliwell's 
often quoted generalisation [29] that transition-metal ions 
invariably catalyse the autoxidation of catecholamines i  
not valid. 
Regarding the disputed role of iron-neuromelanin inter- 
actions [9,14,30], it is interesting to note that melanin, 
whether iron-containing or not, does not catalyse the au- 
toxidation reaction, as shown in Fig. 1. A small deviation 
in the presence of iron-containing melanin at prolonged 
time shows even a slight inhibition of the reaction. This 
observation might deserve further study and might be due 
to properties of the synthetic melanin. However, this does 
not affect the conclusion that neither melanin nor iron-con- 
taining melanin catalyses the autoxidation of DA. 
In view of the sensitivity of the dopaminergic neurons 
to manganese [31,32], it is of particular interest o note that 
manganese(II), alone of the metal ions studied, acts as a 
true catalyst [33] The kinetics of this reaction are compli- 
cated, involving the initial oxidation of the complexed 
manganese to Mn(III), although a small amount of regen- 
erated Mn(II) is responsible for sustaining the chain reac- 
tion. Furthermore, the manganese is not removed from 
solution by incorporation into the neuromelanin (as is the 
case with iron) [34]. 
-0.2 
-0.4 
-0.6 
o ~ -o.8 o~m • -1 O.o, 
-1.2 
-1 .4  - 
0 400 800 1200 1600 2000 
t/s 
Fig. 1. Semilogarithmic concentration/time diagram for the autoxidation 
of DA. 10 mM DA alone (O), and synthetic melanin ([]), iron(Ill) (O) 
and iron(llI)-containing melanin (11) added; pH is 7.6 in 0.100 M KCI. 
Finally, the remarkable activity of nickel(II) in catalyz- 
ing DA autoxidation should be noted (Table 1), as this is a 
highly unusual role for this element. 
3.3. The hydroxylation of dopamine by Fenton's reagent 
A mixture of iron(II) with hydrogen peroxide is known 
as Fenton's Reagent and gains its reactivity from the 
Q 
! 
J 
o 
NINn ieS  
Fig. 2. Time course of the formation of 5-OHDA and 6-OHDA as effect of iron(II) (1 raM) in a mixture of DA (1 mM) and H202 (1 ~)  at 298 K after 5 
(upper trace) and 20 (lower trace) min, respectively, pH is 7.5 in physiological NaCl-solution. 
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formation of hydroxyl radicals Eq. (5). Portions of iron(II) 
and hydrogen peroxide were 
Fe 2++ H202 ~ "OH + OH-+ Fe 3+ (5) 
added to samples of dopamine and the resulting mixture 
analysed by HPLC (as described above) and a successful 
separation and identification of DA, 5-OHDA, and 6- 
OHDA achieved, for which a typical chromatogram is 
shown in Fig. 2. 
These findings are in agreement with the those of 
Cohen et al. [35,36], namely that 5-OHDA and 6-OHDA 
are formed. However, these workers were not able to 
distinguish between these species; they used electrochemi- 
cal detection, applying a potential of + 0.8 V and retention 
times of about 1-2 min after injection. We found under 
similar conditions, but applying the coulometric method of 
detection, a good separation between 5-OHDA and 6- 
OHDA at higher potentials of about 3 V in a reduction 
mode. Using an analogous reversed-phase column, and 
ion-pair chromatography, we found much higher retention 
times of about 10-30 min, with a 1 ml/min flow rate. In 
the region of Cohen's measurements we found only de- 
composition products of the catecholamines. Furthermore, 
we did not use ascorbate buffer in the eluate as did Cohen 
et al. because it is electrochemically active and therefore 
prevents the identification of the HPLC peaks of interest 
(by strong overlapping). 
3.4. Electron transfer between Iron(III) and the dopamines 
The reaction between iron(III) and the dopamines (DA, 
5-OHDA, and 6-OHDA) has been followed by stopped- 
flow techniques. Low pH had to be used to ensure 1:1 
complex formation and thus simulate low DA concentra- 
tions. Typical spectra for the reaction with DA and 6- 
OHDA are shown in Figs. 3 and 4, respectively (5-OHDA 
reacts analogously to DA; under these conditions, we find 
an additional, yet unidentified intermediate [37], whose 
existence, however, does not interfere with our conclusions 
below). 
These spectra show clearly that the initial, rapid, forma- 
tion of an iron(III)-DA complex is followed by relatively 
slow decomposition (by means of internal electron trans- 
fer) to yield iron(II) and the dopamine semiquinone. 
Fig. 4, however, illustrates the completely different 
behaviour of 6-OHDA. There is, from the spectra obtained, 
no evidence for the intermediate formation of an iron(III)- 
6-OHDA complex, suggesting the strong possibility that in 
this case electron transfer proceeds via an 'outer-sphere' 
reaction. It was therefore to be expected that, unlike the 
other dopamines, 6-OHDA would be able to remove iron 
from sources uch as ferritin by means of prior reduction 
of the iron(lII) to iron(II). This has been confirmed by 
Monteiro and Winterbourn [38] and Fig. 5 illustrates the 
time and concentration dependent release of iron from 
ferritin by use of 6-OHDA. 
+ 
Dopamir O(:luinone 
0.300 
0.250 
0,200 
0.150 
0.t00 
0.050 
0 .~ 
(H) ""O 12*/(3+) 
[Fe(H) LH]2+/( 3+ ) 
Wavelength (nm) 
Fig. 3. Time dependent spectra of the reaction of DA (3.0 raM) with 
iron(liD (0.25 mM); pH 2.49 in 0.1 M KCI. Spectra taken after 0.625, 
1.25, 2.50, 5.0, 18.75, 31.25 and 50 s, respectively. Rate of electron 
transfer: 2.25.10 -2 s -I . 
Typical spectra recorded uring the course of the autox- 
idation reaction at neutral pH are shown in Fig. 6. It can be 
seen that (i) general absorption increases due to the forma- 
tion of colloidal melanin, (ii) a peak at 480 nm attributable 
to dopaminochrome appears in the initial stages of the 
reaction but then disappears, (iii) peaks at about 405 and 
620 nm appear in the final stages of the reaction. 
However, in the presence of iron(III), as shown in Fig. 
+ + 
Howl  o 7 
HO/~H NI"13 HO ~ NH3 
6-OH-Dopamine 6-OH-Dopaminoquinone 
0.250 
0.200 
0.150 
0.11~ 
0.11~ i 
0 .~ 
-0.060 
Wavelength (nml 
Fig. 4. Time dependent spectra of the reaction of 6-OHDA (3.0 raM) with 
iron(III) (0.25 raM); pH 2.49 in 0.1 M KC]. Spectra taken after 0.25, 
0.625, 1.25, 2.50, 5.0 and 7.50 s, respectively. Rate of electron transfer: 
600 M- I s  =l . 
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1,4 i 
~ 1.2 
e 
1,0~ 
0.8 
0.6 
0.4 
i 0.2 
Fig. 5. Reductant concentration a d time dependence of the release of 
iron from ferritin in vitro by reduction with 6-OHDA. Iron was monitored 
spectrophotometrically as iron(II) with the colour indicator ferrozin. 
Oo  inoqoioone 0opaminoeh,ome 
~o ¢~ 80o 
7, it is interesting to note that (a) general absorption 
increases and (b) the peak at 405 nm is suppressed by the 
presence of iron(III)-ions, whereas the peak at 620 nm is 
unchanged. Thus, even taking into account hat suppres- 
sion of the 405- nm peak might be due to the increase of 
general absorption, it can be said that iron(III) affects the 
course of melanine-formation, even as it does not catalyse 
the autoxidation reaction. Also it can be seen that the peak 
at 495 nm, due to Fe(LH)~- and masking the less intense 
dopaminochrome peak, disappears during the reaction. 
Since DA is in large excess and its complex a sensitive 
indicator for iron(III), it can be concluded that iron is 
removed from solution, certainly by inclusion into the 
melanin (adsorption of iron at the surface of melanin can 
only account for 5% of the total iron present under our 
conditions [14]). It should be noted that under these condi- 
tions, iron(II) is rapidly oxidised to iron(III). 
3.5. Genera l  d i scuss ion  
The in vitro experiments described above would appear 
to be important and relevant to an understanding of the 
progress of Parkinson's disease: 
1. By use of the confocal fluorescence microscope, it 
can be demonstrated histochemically that excessive hydro- 
gen peroxide accumulation is found in the post mortem 
frontal cortex of a Parkinsonian patient, while in control 
tissue no such associated fluorescent spots could be de- 
tected [39]. This strongly suggests that H20 2 is in fact 
present in the brain (strictly speaking, its presence has 
been shown a few hours after extraction of a brain). It is 
important o note here that the ability of cells to destroy 
peroxides is reduced due to ageing processes. 
2. The fact that 6-OHDA and MPTP (and other reduc- 
ing agents) experimentally induce lesions of the nigrostri- 
atal dopaminergic system (i.e., that they induce effects 
analogous to those evident in Parkinson's disease) is well 
described in the literature [40,41]. That the neurotoxic 
Wavelength (nm) 
Fig. 6. Time-dependent UV-Vis-Spectra during the autoxidation of
dopamine. Spectra were recorded every 300 s, the first (bottom) one 200 
s after the start of the reaction. [DAM] x = 10.0 raM, [02] o = 1.32 raM, 
pH 7.65, I=0.100 M, T=298 K. 
action of MPTP leading to damage of the dopaminergic 
neurons in primates can be blocked by NMDA antagonists 
[42] is also of interest here. 
3. The production of 6-OHDA by a Fenton-type reac- 
tion followed by the release of iron - -  as iron(II) - -  from 
ferritin enables one to suggest he following Scheme 2 by 
which the production of cytotoxic chemicals is sustained. 
As soon as Fe(II) is present (it might occur from ferritine 
by reduction due to 6-OH-DA, MPTP, or other outer 
sphere-reducing agents), OH-radicals or rather Ferryl- 
+ 
Fel Melanine 
+ 
2.0 
o 
Wavelength (nm) 
Fig. 7. Time-dependent UV-Vis-Spectra during the autoxidation of 
dopamine inthe presence of 100 ~M iron(III). Other experimental details 
are given in Fig. 6. 
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species are formed which hydroxylate DA to form 5-, and 
6-OHDA. The latter in turn frees again Fe(I1) from ferri- 
tine. In other words, the left hand, lower part forms an 
autocatalytic ycle continuously producing the cytotoxic 
species like especially OH-radicals or strongly oxidising 
ferryl species. In fact 5-OHDA and 6-OHDA are found in 
human urine - -  especially that of patients undergoing 
dopa therapy [43]. The removal of iron from its storage 
protein by reducing agents such as MPTP while at the 
same time inducing symptoms very similar to PD lends 
added weight to the suggestion that its role in the progres- 
sion of Parkinson's disease is as presented in Scheme 2 
above. 
4. The trapping of iron(III) by melanin as demonstrated 
by the in vitro reaction of DA with 0 2 in the presence of 
iron(III) and its subsequent complete removal from the 
system strongly suggests that one of the functions of 
melanin formation in the SN is the entrapment of any free 
iron(III) to prevent its toxic effects. As mentioned in the 
Introduction, iron-containing melanin has been shown to 
occur significantly in the SN of Parkinson brains; indeed, 
the presence of this melanin can be seen as a result of free 
iron ions in this area rather than as a pathogenic factor in 
its own right. 
5. Investigations concerning the influence of nicotine 
strongly suggest hat the development of Parkinsonism can 
be strongly inhibited by nicotine [44-46]. Nicotine is a 
strong complexing agent for Fe(II) (we obtained a forma- 
tion constant for the Fe(Nic)~ + complex of about 6.5 X 108 
M-2 (more-or-less pH-independent) by spectrophotomet- 
ric titration at 25°C). This observation again strongly rein- 
tbrces the validity of the above proposed mechanism 
(Scheme 2). In fact this might be a hint that it should be 
possible to devise possible treatments for PD based on the 
use of Fe(II)-complexing agents. 
6. Finally, the true catalytic effect of manganese(II) is 
obviously directly related to its toxic effects since it can 
effect the oxidation of DA without subsequently being 
effectively removed from the system (as is the case with 
iron). 
These studies of in vitro chemical reactions considered 
to be important for the development of PD are being 
continued and extended in the belief that this will provide 
a sound chemical basis for the further in vivo studies that 
are required in order to clarify the mechanisms involved in 
the biology of ageing. 
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